Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Tax Provisions (2023 - 2025)

Iovance Biotherapeutics has reported Tax Provisions over the past 3 years, most recently at $229000.0 for Q4 2025.

  • Quarterly results put Tax Provisions at $229000.0 for Q4 2025, down 85.43% from a year ago — trailing twelve months through Dec 2025 was -$2.0 million (up 29.78% YoY), and the annual figure for FY2025 was -$2.1 million, up 26.77%.
  • Tax Provisions for Q4 2025 was $229000.0 at Iovance Biotherapeutics, up from -$2.4 million in the prior quarter.
  • Over the last five years, Tax Provisions for IOVA hit a ceiling of $2.0 million in Q2 2025 and a floor of -$2.4 million in Q3 2025.
  • Median Tax Provisions over the past 3 years was -$1.4 million (2024), compared with a mean of -$753545.5.
  • Biggest five-year swings in Tax Provisions: plummeted 205.66% in 2024 and later surged 237.17% in 2025.
  • Iovance Biotherapeutics' Tax Provisions stood at -$1.8 million in 2023, then surged by 188.36% to $1.6 million in 2024, then plummeted by 85.43% to $229000.0 in 2025.
  • The last three reported values for Tax Provisions were $229000.0 (Q4 2025), -$2.4 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.